| Daniel Miller, | |
|
1600 11th St, Wichita Falls, TX 76301-4300 | |
| (940) 764-7000 | |
| (940) 764-3391 |
| Full Name | Daniel Miller |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 31 Years |
| Location | 1600 11th St, Wichita Falls, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255371811 | NPI | - | NPPES |
| 8P1271 | Other | TX | BCBSTX |
| 044870602 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | J6598 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| United Regional Health Care System | Wichita falls, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wichita Falls Anesthesia Pllc | 7012259260 | 33 |
News Archive
Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.
Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that the Company's popular Gummy Bear products will be distributed in Shanghai, the largest city in China.
Phylogica Ltd, a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.
Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.
Inhaled vaporized cannabis does not appear to improve or worsen exercise performance and activity-related breathlessness in patients with advanced chronic obstructive pulmonary disease, according to a randomized controlled trial published online in the Annals of the American Thoracic Society.
› Verified 1 days ago
| Entity Name | Wichita Falls Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639636210 PECOS PAC ID: 7012259260 Enrollment ID: O20190508002236 |
News Archive
Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.
Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that the Company's popular Gummy Bear products will be distributed in Shanghai, the largest city in China.
Phylogica Ltd, a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.
Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.
Inhaled vaporized cannabis does not appear to improve or worsen exercise performance and activity-related breathlessness in patients with advanced chronic obstructive pulmonary disease, according to a randomized controlled trial published online in the Annals of the American Thoracic Society.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Miller, 3510 N Loop 1604 E, San Antonio, TX 78247-2303 Ph: (210) 375-7790 | Daniel Miller, 1600 11th St, Wichita Falls, TX 76301-4300 Ph: (940) 764-7000 |
News Archive
Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.
Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that the Company's popular Gummy Bear products will be distributed in Shanghai, the largest city in China.
Phylogica Ltd, a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.
Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.
Inhaled vaporized cannabis does not appear to improve or worsen exercise performance and activity-related breathlessness in patients with advanced chronic obstructive pulmonary disease, according to a randomized controlled trial published online in the Annals of the American Thoracic Society.
› Verified 1 days ago
Ky Huynh, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 1600 11th St, Wichita Falls, TX 76301 Phone: 940-764-7000 | |
Dr. Daniel Howard Helbing, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1105 Brook Ave, Wichita Falls, TX 76301 Phone: 940-723-1441 | |
Joseph David Allen Jones, CRNA Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1600 11th St, Wichita Falls, TX 76301 Phone: 940-764-7000 | |
James Godwin, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1600 11th St, Wichita Falls, TX 76301 Phone: 940-764-7000 | |
Susan W Munga, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 501 Midwestern Pkwy E, Wichita Falls, TX 76302 Phone: 940-253-7160 Fax: 833-460-5681 | |
Kari Gee, DNP-A Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1600 11th St, Wichita Falls, TX 76301 Phone: 940-764-7000 |